{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:37:12Z","timestamp":1759667832153},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,8,17]],"date-time":"2014-08-17T00:00:00Z","timestamp":1408233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abiraterone improves survival, relieves pain, improves quality of life and extends time to prostate\u2010specific antigen (<jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>) progression in patients with metastatic castration\u2010resistant prostate cancer (m<jats:styled-content style=\"fixed-case\">CRPC<\/jats:styled-content>). A consensus\u2010based guide for using abiraterone in patients with m<jats:styled-content style=\"fixed-case\">CRPC<\/jats:styled-content> has been developed by <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>ustralian clinicians with expertise in prostate cancer, based on their experience and supported by published data. Recommendations were developed for eight key topics: abiraterone administration; steroid administration and duration of use; concomitant medications and drug interactions; timing of testing and monitoring response; safety in different populations; potential toxicities; precautions and contraindications; and referral and multidisciplinary care. Abiraterone is taken orally in a fasting state. Symptoms associated with mineralocorticoid excess are managed by coadministration of low\u2010dose prednisone or prednisolone. Potassium levels, blood pressure and liver function need to be tested frequently during the early treatment phase. Response to treatment is monitored based on symptoms, radiological imaging and <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content> levels. Potential adverse consequences of long\u2010term steroid therapy on bone and metabolic health need to be screened for and managed. Advanced prostate cancer is best managed by a multidisciplinary team and early referral should be considered. Questions about the potential use of abiraterone in early disease and in combination with other therapies are being addressed in ongoing clinical trials.<\/jats:p>","DOI":"10.1111\/ajco.12264","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T03:19:35Z","timestamp":1408331975000},"page":"228-236","source":"Crossref","is-referenced-by-count":3,"title":["Multidisciplinary consensus: A practical guide for the integration of abiraterone into clinical practice"],"prefix":"10.1111","volume":"10","author":[{"given":"Henry H","family":"Woo","sequence":"first","affiliation":[{"name":"Sydney Adventist Hospital University of Sydney  Wahroonga New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Begbie","sequence":"additional","affiliation":[{"name":"North Coast Cancer Institute University of NSW  Port Macquarie New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Gogna","sequence":"additional","affiliation":[{"name":"Mater Radiation Oncology Centre  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul N","family":"Mainwaring","sequence":"additional","affiliation":[{"name":"ICON Cancer Care  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Declan G","family":"Murphy","sequence":"additional","affiliation":[{"name":"Division of Cancer Surgery Peter MacCallum Cancer Centre University of Melbourne  East Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Parnis","sequence":"additional","affiliation":[{"name":"Adelaide Cancer Centre Tennyson Centre  Kurralta Park South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Steer","sequence":"additional","affiliation":[{"name":"Border Medical Oncology, Wodonga University of NSW Rural Clinical School  Albury New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian D","family":"Davis","sequence":"additional","affiliation":[{"name":"Eastern Health Clinical School Monash University  Box Hill Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,17]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Australian Institute of Health and Welfare.Prostate cancer in Australia. Cancer Series No. 79 (Cat. No. 79). Canberra: AIHW2013."},{"key":"e_1_2_9_3_1","unstructured":"Australian Institute of Health and Welfare & Australasian Association of Cancer Registries.Cancer in Australia: an overview 2012. Cancer Series No. 70 (Cat. No. 70). Canberra: AIHW2012."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20107"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604904"},{"key":"e_1_2_9_6_1","unstructured":"Australian Cancer Network.Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer. CCAAC.2010."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.002"},{"key":"e_1_2_9_8_1","unstructured":"Janssen\u2010Cilag.Product information ZYTIGA\u00ae.2013."},{"key":"e_1_2_9_9_1","unstructured":"Australian Therapeutic Goods Administration.Australian public assessment report for abiraterone citrate (proprietary product name: Zytiga). Australian Government Department of Ageing.2012."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9749"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.1281"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601879"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2815"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9259"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.056"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.6819"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds585"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70473-4"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70424-8"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1617"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.7851"},{"key":"e_1_2_9_24_1","first-page":"S696","article-title":"Evaluation of continuous abiraterone acetate (AA) plus prednisone (P) dosing in fasting and fed states in patients (pts) with metastatic castration\u2010resistant prostate cancer (mCRPC)","volume":"49","author":"Chi KN","year":"2013","journal-title":"Eur J Cancer"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.5170"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2005.1685"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920008784220664"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.8648"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.09.005"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2013.25"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja11.10975"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12264","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.12264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:30:34Z","timestamp":1696339834000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,17]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/ajco.12264"],"URL":"https:\/\/doi.org\/10.1111\/ajco.12264","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,17]]}}}